Precision oncology offerings from JAX Clinical Education
Settings
Save and close
Precision oncology offerings from JAX Clinical Education
Bigger is Not Always Better: What You Should Know Before Ordering a Genomic Tumor Test. Discusses common misconceptions about genomic testing in precision oncology, provide tips for optimizing testing strategy and introduce attendees to additional educational resources.
Choosing the Best Genomic Tumor Test. Learn about the benefits and limitations of different genomic tumor test options for patients with cancer and how to determine the best test for each patient. Free, self-directed program for continuing education credit.
Comparing Cancer Biomarker Tests. Provides information about how cancer biomarker test offerings may differ among laboratories.
Comparing Genetic Tests. Provides a quick reference for the detection capabilities for common types of genetic testing, such as gene sequencing and deletion/duplication analysis.
Evaluating Immune Checkpoint Inhibition Biomarkers. Provides an overview of the benefits and limitations of commonly used immune checkpoint inhibition biomarkers.
Exploring Cancer Biomarker Testing. Learn about benefits, limitations, and challenges of using large somatic cancer panels. Free, self-directed program for continuing education credit.
Facilitating Shared Decision-Making About Genomic Tumor Testing. Supports clinicians when communicating about the process, benefits, and limitations of genomic tumor testing
Familial Adenomatous Polyposis Syndrome factsheet. Describes the clinical features, diagnosis, testing and genetics of Familial Adenomatous Polyposis (FAP) syndrome.
FAQ: Large Panel Genomic Tumor Testing. Describes large panel genomic tumor testing and discusses its benefits, risks, and limitations.
Financial considerations of genomic tumor testing. Help clinicians discuss costs of genomic tumor testing and targeted treatments with their patients, including ways to find financial support.
Genetically Related Cancers. Provides key features and cancer risks associated with common hereditary cancer syndromes.
Hereditary Breast and Ovarian Cancer (HBOC) Syndrome factsheet. Describes the clinical features, diagnosis, testing and genetics of Hereditary Breast and Ovarian Cancer (HBOC) syndrome.
Hereditary Cancer Panels. Provides considerations when evaluating different multigene panels for hereditary cancer testing.
Indications for Germline Testing after Genomic Tumor Testing. Learn how to interpret genomic test results to identify patients with hereditary risks. Free, self-directed program for continuing education credit.
Indications for Germline Testing in Cancer Patients. Provides a quick reference about the factors to consider when determining the appropriateness of germline testing.
Interpreting Cancer Biomarker Testing – When is Additional Testing Needed? Learn when additional cancer biomarker testing is indicated for further evaluation of genome-informed therapy.
Liquid Biopsy: FAQs. Describes the benefits, risks and limitations of liquid biopsy.
Lynch Syndrome factsheet. Describes the clinical features, diagnosis, testing and genetics of Lynch syndrome.
Multidisciplinary Expert Insights: Assessing Hereditary Cancer Risks for Genomic Tumor Testing. A multidisciplinary panel of clinical and laboratory experts discusses a case that highlights factors relevant for the interpretation of tumor results for hereditary risks.
MUTYH-Associated Polyposis Syndrome factsheet. Describes clinical features, diagnosis, testing and genetics of MUTYH-Associated Polyposis (MAP) syndrome.
Ordering & Interpreting PD-L1 testing. Discusses which patients may benefit from PD-L1 testing and how to select and interpret tests for patients with different cancer types.
PARP Inhibitors: Overview and Indications. Discusses FDA-approved indications for PARPi for maintenance therapy and cancer treatment.
Testing to Identify Genomic Variants for Cancer Treatment. Defines and compares benefits and limitations of types of testing: somatic, paired somatic/germline, and concurrent somatic + germline.
Three things to know about genomic tumor test selection. Discusses considerations for choosing the most appropriate genomic tumor test for a patient.
When is pharmacogenomic testing useful in cancer care? Discusses utility of pharmacogenomic testing in cancer care.
Assessing Genomic Variants for Targeted Therapies. Provides a framework for assessing the evidence supporting targeted treatment options.
Bigger is Not Always Better: What You Should Know Before Ordering a Genomic Tumor Test. Discusses common misconceptions about genomic testing in precision oncology, provide tips for optimizing testing strategy and introduce attendees to additional educational resources.
Cancer Biomarker Report Terms. Explains common terms used in cancer biomarker test reports.
Cancer Susceptibility Genes. Lists genes that are associated with hereditary cancer and should be considered for referral when identified on a tumor test report.
Choosing the Best Genomic Tumor Test. Learn about the benefits and limitations of different genomic tumor test options for patients with cancer and how to determine the best test for each patient. Free, self-directed program for continuing education credit.
Exploring Cancer Biomarker Testing. Learn about benefits, limitations, and challenges of using large somatic cancer panels.
Genetic Testing Results Interpretation. Outlines how to interpret results from cancer genetic testing in different patient situations.
Hereditary Cancer Panels. Provides considerations when evaluating different multigene panels for hereditary cancer testing.
Hereditary Cancer Syndromes: Are your Patients at Risk? Develop skills and knowledge to identify those patients most appropriate for genetic testing, choosing the right test, and using the results to develop a management plan. Free, self-directed program.
Homologous Recombination Deficiency (HRD) Testing: FAQs. Provides an overview of biomarkers included in HRD testing.
How to Maximize the Genomic Tumor Board Experience. Suggests ways for you to make the most of the genomic tumor board experience.
Indications for Germline Testing after Genomic Tumor Testing. Learn how to interpret genomic test results to identify patients with hereditary risks. Free, self-directed program for continuing education credit.
Indications for Germline Testing in Cancer Patients. Provides a quick reference about the factors to consider when determining the appropriateness of germline testing.
Interpreting Cancer Biomarker Testing - When is Additional Testing Needed? Learn when additional cancer biomarker testing is indicated for further evaluation of genome-informed therapy. Free, self-directed program for continuing education credit.
Multidisciplinary Expert Insights: Assessing Hereditary Cancer Risks for Genomic Tumor Testing. A multidisciplinary panel of clinical and laboratory experts discusses a case that highlights factors relevant for the interpretation of tumor results for hereditary risks.
Multidisciplinary Expert Insights: Navigating DNA Damage Repair Deficiency in Cancer Patient Management . A multidisciplinary panel of clinical experts discusses a case that involves DNA repair deficiency and PARP inhibitors, including BRCA1/2 and other biomarkers, and how to make informed decisions regarding the best path forward for the patient.
Ordering & Interpreting PD-L1 testing . Discusses which patients may benefit from PD-L1 testing and how to select and interpret tests for patients with different cancer types.
Testing to Identify Genomic Variants for Cancer Treatment . Defines and compares benefits and limitations of types of testing: somatic, paired somatic/germline, and concurrent somatic + germline
Three things to know about DTC breast cancer genetic testing . Discusses the benefits and limitations of direct-to-consumer genetic testing for breast cancer risk
Understanding variants of uncertain significance in somatic cancer panel testing . Describes reasons a genomic variant can have uncertain significance when identified in a tumor.
Assessing Genomic Variants for Targeted Therapies. Provides a framework for assessing the evidence supporting targeted treatment options.
Evaluating Immune Checkpoint Inhibition Biomarkers. Provides an overview of the benefits and limitations of commonly used immune checkpoint inhibition biomarkers.
Familial Adenomatous Polyposis Syndrome factsheet. Describes the clinical features, diagnosis, testing and genetics of Familial Adenomatous Polyposis (FAP) syndrome.
Hereditary Breast and Ovarian Cancer (HBOC) Syndrome factsheet. Describes the clinical features, diagnosis, testing and genetics of Hereditary Breast and Ovarian Cancer (HBOC) syndrome.
Hereditary Cancer Management Guidelines . Provides access to current management guidelines based on genetic or familial risk.
Hereditary Cancer Syndromes: Are your Patients at Risk? Develop skills and knowledge to identify those patients most appropriate for genetic testing, choosing the right test, and using the results to develop a management plan. Free, self-directed program.
How do I get from here to there? Navigating precision medicine in cancer Discusses the role of a genomics navigator to help navigate genetic and genomic testing for cancer patients.
How to Maximize the Genomic Tumor Board Experience. Suggests ways for you to make the most of the genomic tumor board experience.
Immunotherapy - implications for patients with mismatch repair deficient tumors. Discussion of how precision medicine brings personalized treatment options to patients with mismatch repair deficient tumors.
Accessing Off-Label Drugs and Experimental Treatments for Cancer Patients. Provides guidance on how to access off-label drugs and experimental treatments for cancer patients.
Lynch Syndrome factsheet. Describes the clinical features, diagnosis, testing and genetics of Lynch syndrome.
Multidisciplinary Expert Insights: Navigating DNA Damage Repair Deficiency in Cancer Patient Management. A multidisciplinary panel of clinical experts discusses a case that involves DNA repair deficiency and PARP inhibitors, including BRCA1/2 and other biomarkers, and how to make informed decisions regarding the best path forward for the patient.
MUTYH-Associated Polyposis Syndrome factsheet. Describes clinical features, diagnosis, testing and genetics of MUTYH-Associated Polyposis (MAP) syndrome.
PARP Inhibitors: Overview and Indications. Discusses FDA-approved indications for PARPi for maintenance therapy and cancer treatment.
Accessing Genetic Services. Lists tools and websites to help find genetic professionals and provides patient talking points about referring to genetics.
Communicating with Family. Outlines key points to consider when discussing family communication with patients.
Communicating with patients about somatic tumor testing. Provides communication messages about the decision to undergo somatic tumor testing.
Facilitating Shared Decision-Making About Genomic Tumor Testing. Supports clinicians when communicating about the process, benefits, and limitations of genomic tumor testing.
Family History Collection Tips & Tools. Provides tips, resources, and tools for family history collection in clinical practice.
Hereditary Cancer Syndromes: Are your Patients at Risk? Develop skills and knowledge to identify those patients most appropriate for genetic testing, choosing the right test, and using the results to develop a management plan. Free, self-directed program.
Pretest Counseling Recommendations. Outlines key points to address during pretest counseling.